Pearl Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2006-01-01
- Employees
- 51
- Market Cap
- -
Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD
Phase 3
Terminated
- Conditions
- COPD
- Interventions
- Drug: GFF MDI (PT003)Drug: Placebo MDI
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02685293
- Locations
- 🇺🇸
Research Site, Birmingham, Alabama, United States
A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD
Phase 3
Completed
- Conditions
- COPD
- Interventions
- Drug: GFF MDI (PT003) 14.4/9.6μgDrug: Placebo MDI
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02643082
- Locations
- 🇧🇪
Research Site, Edegem, Belgium
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Phase 3
Completed
- Conditions
- COPD
- Interventions
- Drug: GFF MDI 14.4/9.6 μgDrug: BGF MDI 320/14.4/9.6 μgDrug: BFF MDI 320/9.6 μg
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 627
- Registration Number
- NCT02536508
- Locations
- 🇺🇸
Research Site, Morgantown, West Virginia, United States
A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)
Phase 3
Completed
- Conditions
- COPD
- Interventions
- Drug: BFF MDI (PT009) 320/9.6 μgDrug: BGF MDI 320/14.4/9.6 μgDrug: GFF MDI (PT003) 14.4/9.6 μg
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 1902
- Registration Number
- NCT02497001
- Locations
- 🇯🇵
Research Site, Yokohama-shi, Japan
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)
Phase 3
Completed
- Conditions
- COPD
- Interventions
- Drug: BGF MDI 320/14.4/9.6 μgDrug: BFF MDI 320/9.6 μgDrug: BGF MDI 160/14.4/9.6 μgDrug: GFF MDI 14.4/9.6 μg
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 8588
- Registration Number
- NCT02465567
- Locations
- 🇬🇧
Research Site, Wokingham, United Kingdom
Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD
Phase 3
Completed
- Conditions
- COPD
- Interventions
- Device: GFF MDI (PT003) with AerochamberDevice: GFF MDI (PT003) without Aerochamber
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2017-04-19
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02454959
- Locations
- 🇺🇸
Pearl Investigative Site, Gaffney, South Carolina, United States
Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 248
- Registration Number
- NCT02433834
- Locations
- 🇺🇸
Pearl Therapeutics Inc., Waco, Texas, United States
24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo
Phase 3
Completed
- Conditions
- COPD
- Interventions
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2017-04-19
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02347072
24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI
Phase 3
Completed
- Conditions
- COPD
- Interventions
- Drug: GFF MDI (PT003)Drug: Placebo MDI
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2018-07-19
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02347085
Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: GFF MDI (PT003)Drug: GP MDI (PT001)Drug: Placebo MDIDrug: FF MDI (PT005)
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 1756
- Registration Number
- NCT02343458
- Locations
- 🇬🇧
Research Site, Sidcup, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath